We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 58,537 | 08:00:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 29.49M | -302k | -0.0043 | -143.02 | 43.4M |
TIDMTRX
RNS Number : 6258I
Tissue Regenix Group PLC
01 September 2016
Tissue Regenix Group plc
DermaPure(R) Medicare coverage in further 10 States
Leeds, 1(st) September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that effective from today it has gained Medicare coverage in an additional 10 States covered by Medicare jurisdiction National Government Services (NGS) for the use of DermaPure(R).
NGS, whose jurisdiction covers Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont and Wisconsin, has taken the decision to retire their local coverage determination (LCD) for cellular and tissue based products allowing for DermaPure(R) to be eligible for Medicare reimbursement in outpatient settings across these states. This new coverage adds an additional 7.5 million Medicare beneficiaries and means that Tissue Regenix has now secured Medicare reimbursement in 47 States, totalling 93% of traditional Medicare beneficiaries.
DermaPure(R) utilises Tissue Regenix's patented dCELL(R) Technology allowing for a regenerative approach to wound healing and has multiple applications in the treatment of chronic and acute wounds such as diabetic foot ulcers, venous leg ulcers, surgical and trauma wounds.
Patti Gary, VP Clinical Affairs Tissue Regenix Wound Care, Inc. said "We welcome the decision by NGS to retire their LCD allowing for the use of clinically advanced and novel wound care products, which will ultimately benefit the treatment and recovery of patients. We are delighted that DermaPure(R) now has Medicare coverage in 47 States allowing physicians to access and employ our unique dCELL(R) Technology which has the potential to offer superior clinical and economic outcomes."
For more Information:
Tissue Regenix Group plc Tel: 0330 Caitlin Pearson Corporate Communications 430 3073 Officer ========================================== =========== Jefferies International Ltd Tel: 020 Simon Hardy / Harry Nicholas 7029 8000 ========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAEANPFDELKEFF
(END) Dow Jones Newswires
September 01, 2016 02:00 ET (06:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions